Nephrocare Health IPO Subscription Status
Nephrocare Health subscribed over 14.08x on its last day till 5.00 PM on December 12, 2025.
- Nephrocare Health IPO subscription QIB investors’ portion is 26.82 times, while NII subscribed 24.77 times, and RII investors subscribed 2.36 times.
- The company has received bids for 18,69,24,704 shares against 1,32,77,900 shares on offer on the last day of subscription.
Nephrocare Health IPO subscribed over 14.08x on its day 3.
- Nephrocare Health IPO subscribed over 0.37x on its day 2.
- Nephrocare Health IPO subscribed over 0.13x on its day 1.
About Nephrocare Health Company
Nephrocare Health Services Ltd. has been in the business of offering end-to-end dialysis care since 2010, with a large network of clinics across India and international markets. Diagnosis, haemodialysis, home and mobile dialysis, and wellness programs are among the services provided by Nephrocare, which also has its own pharmacy.
The company runs a total of 490 clinics, 447 in India and 43 across the Philippines, Uzbekistan, and Nepal as of March 31, 2025. Currently, the business is present in 269 towns in 21 Indian states and four union territories.
As of March 2025, the company had 5068 dialysis machines serving 29,281 patients and performing over 2.88 million dialysis sessions. Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras, CMRI, Jehangir Hospital, and Ruby Hall Clinic are some of the major hospitals the company partnered with to run an in-house dialysis center.
Nephrocare Health IPO GMP:
Nephrocare Health IPO GMP was ₹20 on Friday, 12 December 2025. That indicates the IPO is trading at ₹480 with a ₹20 premium in the grey market against the issue price of ₹460.
